Skinvisible, Inc. (SKVI) Maximizes Product Development Opportunities with Global Goals
Targeting unmet medical needs with proprietary topical formulations License-based business model translates to worldwide opportunities Patented Invisicare™ technology offers enhanced drug delivery system Global skincare market projected to reach $135 billion by 2021 Research and development company Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI), continues to add significant value to its core business model with several key movements involving a proposed merger, new licensing agreements and formation of a specialized subsidiary. The Company’s November 27 announcement that it has entered into a non-binding term sheet regarding a proposed merger with Quoin Pharmaceuticals Ltd., pending customary closing conditions, melds industry veterans committed to…